The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry - McAllister-Williams RH, Sousa S, Kumar A, Greco T, Bunker MT, Aaronson ST, Conway CR, Rush AJ.
BACKGROUND: To compare illness characteristics, treatment history, response and durability, and suicidality scores over a 5-year period in patients with treatment-resistant bipolar depression participating in a prospective, multicenter, open-label registry... (Source: SafetyLit)
Source: SafetyLit - May 6, 2020 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

Medtronic Rumored to Be Looking at a Deal with LivaNova
Reorg Research reported that Medtronic is in early-stage acquisition talks with LivaNova, news that has been well received by LivaNova shareholders. The firm said Medtronic would subsequently break up LivaNova, keeping its neuromodulation business and selling its cardiovascular business. The article does note, however, that Boston Scientific, Edwards Life Sciences, and Johnson & Johnson may also be interested in the London-based company. Mike Matson, an analyst at Needham & Co., performed a sum-of-parts analysis that values LivaNova's cardiovascular and neuromodulation businesses separately. His analysi...
Source: MDDI - February 28, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Cardiovascular Source Type: news

LivaNova and Verily in Research Agreement to Treat Depression
LivaNova has entered into a research partnership with Verily Life Sciences, an Alphabet company, to evaluate the effectiveness of Vagus Nerve Stimulation (VNS) therapy for Difficult to Treat Depression (DTD). The collaboration comes a few short months after London-based LivaNova ended its transcatheter mitral valve replacement (TMVR) program because of continued declines in revenue from its valve business. In the RECOVER clinical study, LivaNova and Verily aim to gather quantitative data on patient behavior using technology and analytics developed by Verily to further understand depressive episodes and a patientâ ...
Source: MDDI - February 27, 2020 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news

Bioelectronic Research Tackles Hemorrhagic Shock
Jared Huston, MD, a trauma surgeon at Northwell Health on New York's Long Island, spoke straight to the point about the current state of treatment for hemorrhagic shock. While traumatic wounds to extremities can be treated with a tourniquet, such wounds suffered internally are often fatal unless the patient can be transported quickly to an operating room. "There are no efficacious approaches to treating noncompressible hemorrhage," Huston said. "That's really the problem. If you're injured intra-abdominally or in the chest, and you're not brought somewhere where a trauma surgeon can operate on you and stop the bleeding, yo...
Source: MDDI - February 19, 2020 Category: Medical Devices Authors: Greg Goth Tags: Electronics Source Type: news

Feinstein Researchers Demonstrate Long-Term VNS on Mice
The Feinstein Institutes for Medical Research at Northwell Health presented data showing the effective use of a long-term vagus nerve implant in mice at the North American Neuromodulation Society (NANS) 2020 Conference in Las Vegas. Previous preclinical vagus nerve stimulation (VNS) studies have been limited to short-term stimulation - a timeframe of minutes to hours - due to the surgical and technological challenges of implanting a stimulator small enough to fit a mouse nerve. In order to conduct mouse studies lasting weeks or even months, Feinstein Institutes researchers, led by Stavros Zanos, PhD, MD, assistant professo...
Source: MDDI - January 28, 2020 Category: Medical Devices Authors: MDDI Staff Tags: Implants R & D Source Type: news

Auricular electroacupuncture for late posttraumatic epilepsy after severe brain injury: a retrospective study - Shen CC, Jiang JF.
BACKGROUND: Posttraumatic epilepsy (PTE) is a common complication of traumatic brain injury (TBI), which seriously affects patients' survival and recovery. Vagus nerve stimulation (VNS) is a nonpharmacological therapy for epilepsy. The auricular branch of ... (Source: SafetyLit)
Source: SafetyLit - November 20, 2019 Category: International Medicine & Public Health Tags: Environmental Issues, Climate, Geophysics Source Type: news

LivaNova Enrolls 1st Patient in RECOVER Depression Treatment Study
The objectives of the RECOVER study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity. The study will include up to 500 unipolar and up to 500 bipolar patients at as many as 100 sites in the U.S. RECOVER is a double-blind, randomized, placebo-controlled study with a follow-up duration of at least one year. The CMS study framework also includes the possibility to extend to a prospective longitudinal study. While VNS Therapy received CE Mark in 2001 and FDA approval in 2005 for the treatment of depression, last month,...
Source: MDDI - September 30, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Quick, Noninvasive Approach Promising for Migraine With Vertigo Quick, Noninvasive Approach Promising for Migraine With Vertigo
Noninvasive vagus nerve stimulation provides rapid relief of vertigo and headache in patients with acute vestibular migraine, results of a small study suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 30, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Could a 'Tickle' a Day Keep the Doctor Away?
The tickle treatment is called transcutaneous vagus nerve stimulation (tVNS). The procedure involves placing custom-made clips containing electrodes on the part of your ear called the tragus; that's the small, pointed tip above your ear lobe. (Source: WebMD Health)
Source: WebMD Health - August 5, 2019 Category: Consumer Health News Source Type: news

Medical News Today: Vagus nerve stimulation may reduce the symptoms of rheumatoid arthritis
A new study suggests that electrostimulation of the vagus nerve may reduce the symptoms of rheumatoid arthritis and other chronic inflammatory conditions. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 24, 2019 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

Vagal Stimulation Lessens Paroxysmal AF in Sham-Controlled Study Vagal Stimulation Lessens Paroxysmal AF in Sham-Controlled Study
AF burden fell significantly over 6 months for patients receiving electrical vagus nerve stimulation in daily 1-hour sessions in a small randomized study that invites confirmation in larger trials.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 16, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Non-invasive vagus nerve stimulation shows promise for treatment of rheumatoid arthritis
(Northwell Health) Bioelectronic medicine scientists at The Feinstein Institute for Medical Research collaborated with counterparts from Academic Medical Center at University of Amsterdam in the Netherlands to carry out a series of pilot clinical studies to assess the effect of a novel bioelectronic stimulation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 16, 2019 Category: International Medicine & Public Health Source Type: news

LivaNova ’ s CMS vagus nerve depression device trial must include sham arm
A new U.S. Centers for Medicare & Medicaid Services trial of LivaNova‘s (NSDQ:LIVN) Vagus Nerve Stimulation Therapy system intended to treat treatment-resistant depression will require a sham-control arm, doubling the subject population LivaNova originally expected. The trial, which the London-based company won clearance from CMS for last month, will allow coverage for the VNS devices through a Coverage with Evidence Development framework. As revealed last month, the trial will be double-blinded, randomized and feature a follow-up of at least one year, the company said. New data, revealed in a posting on Clinical...
Source: Mass Device - March 27, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neurological LivaNova Source Type: news

Cala Health licenses MGH-developed neuromod tech
Cala Health said this week it inked a deal to license technology from Partners Healthcare and its affiliate Massachusetts General Hospital intended to improve the company’s non-invasive neuromodulation platform for investigating and treating chronic diseases. The licensed technology was developed from research on transcutaneous vagus nerve stimulation and respiratory-gated vagal afferent nerve stimulation at a research lab in the MGH, the Burlingame, Calif.-based company said. “This collaboration with MGH’s cutting-edge research team provides a clear opportunity to accelerate development of wearable neuromodu...
Source: Mass Device - March 14, 2019 Category: Medical Devices Authors: Fink Densford Tags: Neurological Neuromodulation/Neurostimulation Research & Development Cala Health Source Type: news

LivaNova shares dip despite Q4, 2018 earnings beat
Shares in LivaNova (NSDQ:LIVN) fell today despite the medical device maker posting fourth quarter and full year 2018 earnings that topped expectations on Wall Street. The London-based company posted losses of $210.6 million, or $4.34 per share, on sales of $297 million for the three months ended December 31, seeing losses grow 88.5% while sales grew 6.7% compared with the same period during the previous year. Adjusted to exclude one-time items, earnings per share were $1.12, just ahead of the $1.10 consensus on Wall Street where analysts expected to see sales of $295 million, which the company topped. For the full year, L...
Source: Mass Device - February 27, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat LivaNova Source Type: news